Sector Gamma AS Has $17.19 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sector Gamma AS lessened its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 141,218 shares of the medical equipment provider’s stock after selling 17,851 shares during the quarter. Zimmer Biomet accounts for 4.2% of Sector Gamma AS’s portfolio, making the stock its 9th largest position. Sector Gamma AS owned about 0.07% of Zimmer Biomet worth $17,186,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. PFG Advisors raised its holdings in shares of Zimmer Biomet by 4.6% in the 4th quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock valued at $231,000 after purchasing an additional 84 shares in the last quarter. Quent Capital LLC grew its position in shares of Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after buying an additional 92 shares during the last quarter. Pinnacle Associates Ltd. grew its position in shares of Zimmer Biomet by 5.0% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock worth $227,000 after buying an additional 97 shares during the last quarter. Financial Advocates Investment Management grew its position in shares of Zimmer Biomet by 3.8% in the 3rd quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock worth $295,000 after buying an additional 97 shares during the last quarter. Finally, Stokes Family Office LLC grew its position in shares of Zimmer Biomet by 4.1% in the 3rd quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock worth $280,000 after buying an additional 99 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded down $0.40 during trading hours on Friday, reaching $119.35. 1,099,241 shares of the company’s stock were exchanged, compared to its average volume of 1,046,552. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $149.25. The company has a market capitalization of $24.52 billion, a P/E ratio of 24.41, a price-to-earnings-growth ratio of 2.20 and a beta of 1.01. The business has a fifty day moving average of $125.98 and a two-hundred day moving average of $119.52. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same quarter in the prior year, the firm earned $1.88 earnings per share. The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is currently 19.63%.

Insider Activity at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now owns 44,145 shares of the company’s stock, valued at $5,677,929.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.95% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ZBH. Citigroup lifted their price objective on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Evercore ISI lifted their price objective on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. StockNews.com downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 9th. Finally, Barclays boosted their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research report on Monday, February 12th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $139.39.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.